Efficacy and safety of pembrolizumab in patients with advanced mesothelioma in the open-label, single-arm, phase 2 KEYNOTE-158 study-Reference-Cited by-同舟云学术

Efficacy and safety of pembrolizumab in patients with advanced mesothelioma in the open-label, single-arm, phase 2 KEYNOTE-158 study

Published:2021-06 Issue:6 Volume:9 Page:613-621
ISSN:2213-2600
Container-title:The Lancet Respiratory Medicine
language:en
Short-container-title:The Lancet Respiratory Medicine

Author:

Yap Timothy A,Nakagawa Kazuhiko,Fujimoto Nobukazu,Kuribayashi Kozo,Guren Tormod Kyrre,Calabrò Luana,Shapira-Frommer Ronnie,Gao Bo,Kao Steven,Matos Ignacio,Planchard David,Chatterjee Arkendu,Jin Fan,Norwood Kevin,Kindler Hedy L

Publisher

Elsevier BV

Subject

Pulmonary and Respiratory Medicine

Reference28 articles.

1. Heterogeneous contributing factors in MPM disease development and progression: biological advances and clinical implications;Tolani;Int J Mol Sci,2018

2. Malignant pleural mesothelioma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up;Baas;Ann Oncol,2015

3. Pemetrexed disodium in combination with cisplatin versus other cytotoxic agents or supportive care for the treatment of malignant pleural mesothelioma;Green;Cochrane Database Syst Rev,2007

4. Taken together: effective multimodal approaches for malignant pleural mesothelioma;Song;Thorac Surg Clin,2020

5. Immunotherapy for mesothelioma: rationale and new approaches;Reuss;Clin Adv Hematol Oncol,2020

Cited by 49 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Pembrolizumab-induced vasculitis demonstrated by FDG-PET/CT;Radiology Case Reports;2024-09

2. Case report: complete response and long-term survival on third-line immunotherapy in patient with pleural mesothelioma;Frontiers in Oncology;2024-08-29

3. Emerging biomarkers for immunotherapy response in biliary tract cancers: a comprehensive review of immune checkpoint inhibitor strategies;Biomarkers in Medicine;2024-08-15

4. Genomic and T cell repertoire biomarkers associated with malignant mesothelioma survival;Thoracic Cancer;2024-05-27

5. Consensus Guideline for the Management of Patients with Peritoneal Mesothelioma;2024-04-13